BMS-986278
- Generic Name
- BMS-986278
- Drug Type
- Small Molecule
- Chemical Formula
- C22H31N5O5
- CAS Number
- 2170126-74-4
- Unique Ingredient Identifier
- 4UN9AOU6G8
A Study Investigating the Safety, Tolerability, Drug Levels and Drug Effect of BMS-986278 in Healthy Adult Participants (Part 1) and Japanese Participants (Part 2)
Phase 1
Completed
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2023-01-13
- Last Posted Date
- 2023-08-24
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 61
- Registration Number
- NCT05684289
- Locations
- 🇺🇸
Syneos Health Clinical Research Services, Llc, Miami, Florida, United States
🇺🇸Altasciences Clinical Los Angeles, Inc, Cypress, California, United States
Study to Assess the Way the Body Absorbs, Distributes, Breaks Down and Eliminates Radioactive BMS-986278 in Healthy Male Participants
- First Posted Date
- 2020-09-28
- Last Posted Date
- 2022-06-02
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 9
- Registration Number
- NCT04567667
- Locations
- 🇺🇸
Covance - Clinical Pharmacology Services - Madison, Madison, Wisconsin, United States
A Study to Assess the Levels in Blood Plasma of BMS-986278 in Healthy Participants Following Administration of Tablets, With or Without Food, and in the Presence of an Antacid (Esomeprazole)
Phase 1
Completed
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2020-07-13
- Last Posted Date
- 2022-05-10
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 24
- Registration Number
- NCT04468815
- Locations
- 🇺🇸
ICON (LPRA) - Salt Lake, Salt Lake City, Utah, United States
A Study Measuring the Effectiveness, Safety, and Tolerability of BMS-986278 in Participants With Lung Fibrosis
- First Posted Date
- 2020-03-16
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 403
- Registration Number
- NCT04308681
- Locations
- 🇨🇳
Local Institution - 0174, Taipei, Taiwan
🇨🇳Local Institution - 0175, Taipei, Taiwan
🇬🇧Local Institution - 0050, Cambridge, United Kingdom
A Study of the Pharmacokinetic Interaction Between Pirfenidone and BMS-986278 in Healthy Participants
Phase 1
Completed
- Conditions
- Idiopathic Pulmonary Fibrosis (IPF)
- Interventions
- First Posted Date
- 2019-06-10
- Last Posted Date
- 2020-05-15
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 22
- Registration Number
- NCT03981094
- Locations
- 🇺🇸
PRA Health Sciences - Salt Lake, Salt Lake City, Utah, United States
An Investigational Study of Experimental Medication BMS-986278 Given With the Antibiotic Rifampin in Healthy Participants
- First Posted Date
- 2018-10-19
- Last Posted Date
- 2019-06-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 39
- Registration Number
- NCT03712540
- Locations
- 🇺🇸
PRA Health Science KK, Lenexa, Kansas, United States
A Study of Experimental Medication BMS-986278 Given to Healthy Participants
- First Posted Date
- 2018-02-12
- Last Posted Date
- 2019-10-01
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 112
- Registration Number
- NCT03429933
- Locations
- 🇬🇧
Local Institution, London, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath